Sugi Predict

Sugi Predict / Compounds / SCHEMBL522141

SCHEMBL522141

SCHEMBL522141

Cc1cc(N)ccc1C1CCN(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 2/20 0.56
▸ HTR1B P28222 2/20 0.56
▸ ADRA2C P18825 2/20 0.42
▸ HTR1F P30939 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ GAA P10253 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ PTK2B Q14289 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ NR4A1 P22736 1/20 0.41
▸ QDPR P09417 2/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ THPO P40225 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ RAD52 P43351 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30962926 0.94 HTR1D (0.51) HTR1DHTR1BADRA2CHTR1FALDH1A1
SCHEMBL10127647 0.91 HTR1D (0.52) HTR1DHTR1BADRA2CHTR1FALDH1A1
SCHEMBL23334746 0.85 ALDH1A1 (0.50) HTR1DHTR1BALDH1A1GAAMAPT
SCHEMBL13723802 0.83 HTR1D (0.43) HTR1DHTR1BALDH1A1GAAMAPT
SCHEMBL17642598 0.82 QDPR (0.42) HTR1DHTR1BALDH1A1KMT2AMEN1
SCHEMBL13724208 0.82 SOS1 (0.42) HTR1DHTR1BALDH1A1GAAMAPT
SCHEMBL12070784 0.82 GAA (0.54) HTR1DHTR1BALDH1A1GAAMAPT
SCHEMBL13728741 0.82 HTR1D (0.40) HTR1DHTR1BALDH1A1GAAMAPT
SCHEMBL22640335 0.82 ALDH1A1 (0.46) HTR1DHTR1BALDH1A1GAAMAPT
SCHEMBL10036444 0.82 SLC18A3 (0.48) HTR1DHTR1BGAAMAPTRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
EP-4619406-A1 TRICYCLIC COMPOUNDS Schrödinger, Inc. (US) 2025-09-24 — — EP disclosed
WO-2025042408-A1 METHODS OF TREATING CANCER SCHRÖDINGER, INC. (US) 2025-02-27 — — WO disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 — — WO disclosed
CN-118084919-A Preparation method and intermediate of dihydropyrimidinone pyrimidine compound 上海凌凯医药科技有限公司 2024-05-28 — — CN disclosed
WO-2024107393-A1 TRICYCLIC COMPOUNDS SCHRÖDINGER, INC. (US) 2024-05-23 — — WO disclosed
US-20240010655-A1 DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND Impact Therapeutics (Shanghai), Inc (CN) 2024-01-11 — — US disclosed
WO-2023217201-A2 NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF 杭州德睿智药科技有限公司 2023-11-16 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 — — US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 — — US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 — — EP disclosed
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES SAGARA TAKESHI 2011-08-04 — — US disclosed
US-7935708-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2011-05-03 — — US disclosed
US-7834019-B2 Substituted pyrazolo[3,4-d]pyrimidinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 — — US disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 — — WO disclosed
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives MERCK SHARP & DOHME LLC 2010-03-11 — — US disclosed
EP-2017278-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-01-21 — — EP disclosed
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2007-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 HTR1D 776/4885HTR1B 1737/4885ADRA2C 1278/4885
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives WEE1, WEE2, GRK3 HTR1D 776/4885HTR1B 1737/4885ADRA2C 1278/4885
US-20240010655-A1 DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND WEE1, WEE2, NME1 HTR1D 4122/4885HTR1B 4565/4885ADRA2C 4205/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HTR1D 3635/4885HTR1B 3677/4885ADRA2C 4411/4885
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives WEE1, WEE2, GRK3 HTR1D 776/4885HTR1B 1737/4885ADRA2C 1278/4885
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B HTR1D 4471/4885HTR1B 4632/4885ADRA2C 4757/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK HTR1D 2001/4885HTR1B 1759/4885ADRA2C 1271/4885
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 HTR1D 3024/4885HTR1B 2523/4885ADRA2C 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.